Join us for our third IRD Invest virtual investor conference to hear from a range of Australian listed companies that are innovating by addressing new and changing needs in patient care.
PRESENTERS: Thursday 23rd September
Dr James Garner, CEO & Executive Director, Kazia Therapeutics Limited (ASX: KZA)
Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Its lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.
11.00 – 11.25am
Michelle Gallaher, Chief Executive Officer, Opyl Limited (ASX:OPL)
Opyl is an Australian company that provides leading biopharma and health organisations access to emerging AI-assisted technologies and real-world data insights to understand and improve healthcare design, development, and delivery.
11.30 – 11.55am
Brian Leedman, Non Executive Director, Neurotech International Limited (ASX: NTI)
Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis
12.00 – 12.25pm
Dr Tim Oldham, CEO and Managing Director, AdAlta Limited (ASX: 1AD)
AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics.
Race 12.30 – 12.55pm
Phil Lynch, CEO and Dr Daniel Tillett, CSO, Race Oncology (ASX:RAC)
Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene® (bisantrene dihydrochloride). Zantrene® is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein.